Mayo 2015.

Methods	Randomised clinical trial.
Participants	Country: multicentric; international. Number randomised: 45. Post‐randomisation dropouts: 3 (6.7%). Revised sample size: 42. Mean age: 56 years. Females: 38 (90.5%). Symptomatic participants: not stated. AMA positive: not stated. Responders: not stated. Mean follow‐up period (for all groups): not stated. Inclusion criteria Symptom status: not stated. AMA status: not stated. Response status: not stated.
Interventions	Participants were randomly assigned to 2 groups. Group 1: NGM282 (n = 27). Further details: NGM282: 0.3 mg/day or 3 mg/day SC for 28 days. Group 2: placebo (n = 15).
Outcomes	None of the outcomes of interest reported.
Notes	Reasons for post‐randomisation dropouts: not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: information not available.
Allocation concealment (selection bias)	Unclear risk	Comment: information not available.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: although placebo was used in this double‐blind trial, unclear whether the placebo was identical.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: although placebo was used in this double‐blind trial, unclear whether the placebo was identical.
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: there were post‐randomisation dropouts.
Selective reporting (reporting bias)	High risk	Comment: neither mortality nor adverse events reported.
For‐profit bias	High risk	Quote: "Grant/Research Support: Intercept, Salix, NGM, Lumena, Gilead".
Other bias	Low risk	Comment: no other bias.